Business Context and Reporting Period
Company: 60 Degrees Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 28, 2025 (Event Date)
Closing Date: January 30, 2025
Context: The Company, an emerging growth company, entered into a Securities Purchase Agreement to conduct a registered direct offering of common stock and a concurrent private placement of warrants.
Key Financial Metrics and Transaction Details
| Metric | Value |
|---|---|
| Shares Sold (Common Stock) | 1,021,549 |
| Purchase Price per Share | $1.021 |
| Gross Proceeds (Estimated) | $1,043,001.53 |
| Net Proceeds | $804,346.40 |
| Warrants Issued to Purchasers | 2,043,098 (to purchase Warrant Shares) |
| Warrant Exercise Price | $0.771 per share |
| Warrant Expiration | 24 months from issuance |
| Placement Agent Fees | 7.5% transaction fee + 1.0% management fee |
| Other Expenses | $25,000 (non-accountable and clearing fees) |
Note: The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Transaction Structure
- Capital Raise: The Company raised approximately $804,000 in net proceeds through the sale of common stock and warrants.
- Warrant Terms: Purchasers received warrants to buy 2x the number of shares purchased. Exercise is subject to a beneficial ownership limitation of 4.99% (or 9.99% upon election) to prevent dilution beyond this threshold without a 61-day waiting period.
- Placement Agent Compensation: H.C. Wainwright & Co., LLC served as the exclusive placement agent. In addition to cash fees, the agent received warrants to purchase 76,616 shares at an exercise price of $1.2763 per share.
- Registration Obligation: The Company must file a registration statement for the Warrant Shares within 45 days of the agreement and use commercially reasonable efforts to make it effective within 75 days.
Outlook, Management Commentary, and Risks
- Use of Proceeds: Net proceeds are designated for general corporate purposes, including working capital.
- Market Status: The offering was priced at-the-market under Nasdaq rules.
- Risks/Contingencies: The filing notes standard risks associated with warrant exercise limitations and the requirement to maintain registration effectiveness for the Warrant Shares. No specific operational risks or unusual items were detailed beyond the transaction mechanics.
Investor Verification Checklist
- Verify the final number of shares outstanding post-offering to assess immediate dilution.
- Confirm the effective date of the registration statement for the Warrant Shares (required within 75 days of closing).
- Review the Company's cash runway and burn rate to understand the sufficiency of the $804,346 net proceeds for working capital needs.
- Monitor the trading price of the Common Stock relative to the Warrant exercise price ($0.771) to gauge the likelihood of warrant exercise.